Currently out of the existing stock ratings of Maury Raycroft, 83 are a BUY (79.81%), 21 are a HOLD (20.19%).

Maury Raycroft

Work Performance Price Targets & Ratings Chart

Analyst Maury Raycroft, currently employed at JEFFERIES, carries an average stock price target met ratio of 51.13% that have a potential upside of 35.97% achieved within 146 days.

Maury Raycroft’s has documented 227 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BCRX, BioCryst Pharmaceuticals at 03-Nov-2023.

Wall Street Analyst Maury Raycroft

Analyst best performing recommendations are on VERA (VERA THERAPEUTICS).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS) at 9/18/2017. The price target of $102 was fulfilled within 2 days with a profit of $26 (34.21%) receiving and performance score of 171.05.

Average potential price target upside

AFMD Affimed NV ARWR Arrowhead Pharmaceuticals ATRA Atara Biotherapeutics AYLA Ayala Pharmaceuticals  BCRX BioCryst Pharmaceuticals CRBP Corbus Pharmaceuticals CRSP Crispr Therapeutics AG KALV Kalvista Pharmaceuticals MRTX Mirati Ther RETA Reata Pharmaceuticals SRRA Sierra Oncology ALLK Allakos ABEO Abeona Therapeutics ALNY Alnylam Pharmaceuticals EIGR Eiger Biopharmaceuticals NTLA Intellia Therapeutics BYSI BeyondSpring VALN Valneva SE ADR XENE Xenon Pharmaceuticals FMTX Forma Therapeutics Holdings KPTI Karyopharm Therapeutics RARE Ultragenyx SGMO Sangamo Therapeutics IMGO Imago Biosciences VERA Vera Therapeutics CNST Constellation Pharmaceuticals RTRX Travere Therapeutics SBPH Spring Bank Pharmaceuticals THRX Theseus Pharmaceuticals TYRA Tyra Biosciences RZLT Rezolute SPPI Spectrum Pharmaceuticals KZR Kezar Life Sciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

10

$4.85 (94.17%)

10

1 months 1 days ago

0/3 (0%)

$2.91 (41.04%)

Buy

25

$19.85 (385.44%)

110

1 months 1 days ago

2/3 (66.67%)

$17.91 (252.61%)

348

Hold

5

$-0.15 (-2.91%)

20

3 months 13 days ago

2/3 (66.67%)

$-1.35 (-21.26%)

25

Buy

3 months 13 days ago

1/2 (50%)

$-33.5 (-73.63%)

246

Buy

25

$19.85 (385.44%)

3 months 13 days ago

0/1 (0%)

$18.65 (293.70%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Maury Raycroft?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?